Huston Pamela A, Hoover Darren L
Everett and Hurite Ophthalmic Association, Pittsburgh, Pennsylvania.
Everett and Hurite Ophthalmic Association, Pittsburgh, Pennsylvania.
J AAPOS. 2015 Oct;19(5):417-21. doi: 10.1016/j.jaapos.2015.06.004.
To evaluate the efficacy of a home-based computer orthoptic program for symptomatic convergence insufficiency (CI) in children.
The medical records of participants aged 5 to <18 years who were diagnosed with symptomatic CI and were treated with the Computerized Vergence System (CVS) program were retrospectively reviewed. All participants were prescribed 9 or 15 minutes of daily convergence exercises with the CVS program, 5 days per week, for the initial 6 weeks. Near point of convergence (NPC) and near convergence amplitude (NCA) were measured at baseline, 6 week, and final examinations. The presence or absence of diplopia and asthenopia with reading were recorded at baseline and final examinations.
A total of 186 participants were included. At diagnosis, 72 participants (39%) reported diplopia and 182 (98%), reported asthenopia. At final examination, 172 participants (92%) were asymptomatic. Twelve participants (6%) subsequently received other treatment modalities. Mean NPC at baseline (5.9 cm) improved after 6 weeks of CVS therapy (3.3 cm) and at final examination (2.9 cm; P < 0.0005). Mean NCA at baseline (20.3(Δ)) improved after 6 weeks of CVS therapy (37.0(Δ)) and at the final examination (38.0(Δ); P < 0.0005).
In this study, home-based CVS therapy reduced symptoms related to CI and improved the NPC and NCA of most children aged 5 to <18 years with symptomatic CI.
评估基于家庭的计算机视轴矫正程序对儿童症状性集合不足(CI)的疗效。
回顾性分析5至18岁被诊断为症状性CI并接受计算机化集合系统(CVS)程序治疗的参与者的病历。所有参与者在最初6周内,每周5天,每天使用CVS程序进行9或15分钟的集合训练。在基线、6周和最终检查时测量集合近点(NPC)和近集合幅度(NCA)。在基线和最终检查时记录阅读时复视和视疲劳的有无。
共纳入186名参与者。诊断时,72名参与者(39%)报告有复视,182名(98%)报告有视疲劳。在最终检查时,172名参与者(92%)无症状。12名参与者(6%)随后接受了其他治疗方式。CVS治疗6周后,基线时的平均NPC(5.9厘米)有所改善(3.3厘米),在最终检查时(2.9厘米;P<0.0005)。CVS治疗6周后,基线时的平均NCA(20.3(Δ))有所改善(37.0(Δ)),在最终检查时(38.0(Δ);P<0.0005)。
在本研究中,基于家庭的CVS治疗减轻了与CI相关的症状,并改善了大多数5至18岁有症状性CI儿童的NPC和NCA。